Zhitong Financial App News, Maiwei Biotech (688062.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for 9MW5211 injection for vitiligo indications was approved. Previously, its clinical trial application for inflammatory bowel disease (IBD) indications had been approved by the National Drug Administration and FDA approval respectively. Clinical trial applications for multiple sclerosis (MS) and type 1 diabetes (T1DM) indications have been approved by the China Drug Administration .

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.